Zidovudine/Lamivudine vs. Abacavir/Lamivudine vs. Tenofovir/Emtricitabine in fixed-dose combinations as initial treatment for HIV patients: a systematic review and network meta-analysis
ABSTRACT: Initial treatment of the HIV is based on the use of three drugs, two of which are nucleoside analog reverse-transcriptase inhibitors. There are three combinations of these drugs which have been approved by different guidelines, each with divergent results in terms of efficacy and safety. T...
- Autores:
-
Alzate Angel, Juan Carlos
Duque Molina, Marcela María
García García, Héctor Iván
- Tipo de recurso:
- Review article
- Fecha de publicación:
- 2017
- Institución:
- Universidad de Antioquia
- Repositorio:
- Repositorio UdeA
- Idioma:
- eng
spa
- OAI Identifier:
- oai:bibliotecadigital.udea.edu.co:10495/19601
- Acceso en línea:
- http://hdl.handle.net/10495/19601
- Palabra clave:
- VIH
HIV
Emtricitabina
Emtricitabine
Tenofovir
Zidovudina
Zidovudine
Combinación de Medicamentos
Drug Combinations
Revisión Sistemática
Systematic Review
- Rights
- openAccess
- License
- http://creativecommons.org/licenses/by-nc-nd/2.5/co/
| id |
UDEA2_7c81799a0b1283b920b12951e0019b3f |
|---|---|
| oai_identifier_str |
oai:bibliotecadigital.udea.edu.co:10495/19601 |
| network_acronym_str |
UDEA2 |
| network_name_str |
Repositorio UdeA |
| repository_id_str |
|
| dc.title.spa.fl_str_mv |
Zidovudine/Lamivudine vs. Abacavir/Lamivudine vs. Tenofovir/Emtricitabine in fixed-dose combinations as initial treatment for HIV patients: a systematic review and network meta-analysis |
| dc.title.translated.spa.fl_str_mv |
Zidovudina/Lamivudina vs Abacavir/Lamivudina vs Tenofovir/Emtricitabina en combinaciones de dosis fija como tratamiento inicial en pacientes con VIH: revisión sistemática y metanálisis en red |
| title |
Zidovudine/Lamivudine vs. Abacavir/Lamivudine vs. Tenofovir/Emtricitabine in fixed-dose combinations as initial treatment for HIV patients: a systematic review and network meta-analysis |
| spellingShingle |
Zidovudine/Lamivudine vs. Abacavir/Lamivudine vs. Tenofovir/Emtricitabine in fixed-dose combinations as initial treatment for HIV patients: a systematic review and network meta-analysis VIH HIV Emtricitabina Emtricitabine Tenofovir Zidovudina Zidovudine Combinación de Medicamentos Drug Combinations Revisión Sistemática Systematic Review |
| title_short |
Zidovudine/Lamivudine vs. Abacavir/Lamivudine vs. Tenofovir/Emtricitabine in fixed-dose combinations as initial treatment for HIV patients: a systematic review and network meta-analysis |
| title_full |
Zidovudine/Lamivudine vs. Abacavir/Lamivudine vs. Tenofovir/Emtricitabine in fixed-dose combinations as initial treatment for HIV patients: a systematic review and network meta-analysis |
| title_fullStr |
Zidovudine/Lamivudine vs. Abacavir/Lamivudine vs. Tenofovir/Emtricitabine in fixed-dose combinations as initial treatment for HIV patients: a systematic review and network meta-analysis |
| title_full_unstemmed |
Zidovudine/Lamivudine vs. Abacavir/Lamivudine vs. Tenofovir/Emtricitabine in fixed-dose combinations as initial treatment for HIV patients: a systematic review and network meta-analysis |
| title_sort |
Zidovudine/Lamivudine vs. Abacavir/Lamivudine vs. Tenofovir/Emtricitabine in fixed-dose combinations as initial treatment for HIV patients: a systematic review and network meta-analysis |
| dc.creator.fl_str_mv |
Alzate Angel, Juan Carlos Duque Molina, Marcela María García García, Héctor Iván |
| dc.contributor.author.none.fl_str_mv |
Alzate Angel, Juan Carlos Duque Molina, Marcela María García García, Héctor Iván |
| dc.contributor.researchgroup.spa.fl_str_mv |
Grupo Académico de Epidemiología Clínica |
| dc.subject.decs.none.fl_str_mv |
VIH HIV Emtricitabina Emtricitabine Tenofovir Zidovudina Zidovudine Combinación de Medicamentos Drug Combinations Revisión Sistemática Systematic Review |
| topic |
VIH HIV Emtricitabina Emtricitabine Tenofovir Zidovudina Zidovudine Combinación de Medicamentos Drug Combinations Revisión Sistemática Systematic Review |
| description |
ABSTRACT: Initial treatment of the HIV is based on the use of three drugs, two of which are nucleoside analog reverse-transcriptase inhibitors. There are three combinations of these drugs which have been approved by different guidelines, each with divergent results in terms of efficacy and safety. To compare the efficacy and safety of these three combinations. Systematic review and network meta-analysis of randomized clinical trials comparing fixed doses of Tenofovir Disoproxil Fumarate / Emtricitabine (TDF/FTC), Abacavir / Lamivudine (ABC/3TC) and Zidovudine / Lamivudine (ZDV/3TC). Seven clinical trials met the eligibility criteria. The results suggested higher efficacy with TDF/FTC vs. ABC/3TC at 96 weeks and vs. ZDV/3TC at 48 weeks. However, there is clinical and statistical heterogeneity. Subgroup analysis were performed by third drug and by level of viral load prior to treatment, and found no differences in virological control. Network meta-analysis could only be carried out with TDF/FTC vs. ZDV/3TC, and the proportion of patients with virological response, with no differences at 48 weeks nor at 96 weeks. Direct comparisons showed an increased risk of bone marrow suppression of ZDV/3TC vs. TDF/FTC and of ABC/3TC hypersensitivity reactions vs. ZDV/3TC. The results did not show differences in effectiveness among the interventions. However, due to the heterogeneity of the third drug and the follow-up time between the included studies, this result is not definitive. The results raise the need for further studies to help improve treatment recommendations in patients infected with HIV. |
| publishDate |
2017 |
| dc.date.issued.none.fl_str_mv |
2017 |
| dc.date.accessioned.none.fl_str_mv |
2021-05-14T15:44:18Z |
| dc.date.available.none.fl_str_mv |
2021-05-14T15:44:18Z |
| dc.type.spa.fl_str_mv |
Artículo de revisión |
| dc.type.coar.fl_str_mv |
http://purl.org/coar/resource_type/c_2df8fbb1 |
| dc.type.coar.spa.fl_str_mv |
http://purl.org/coar/resource_type/c_dcae04bc |
| dc.type.redcol.spa.fl_str_mv |
https://purl.org/redcol/resource_type/ARTREV |
| dc.type.coarversion.spa.fl_str_mv |
http://purl.org/coar/version/c_970fb48d4fbd8a85 |
| dc.type.driver.spa.fl_str_mv |
info:eu-repo/semantics/article |
| dc.type.version.spa.fl_str_mv |
info:eu-repo/semantics/publishedVersion |
| format |
http://purl.org/coar/resource_type/c_dcae04bc |
| status_str |
publishedVersion |
| dc.identifier.issn.none.fl_str_mv |
1657-9534 |
| dc.identifier.uri.none.fl_str_mv |
http://hdl.handle.net/10495/19601 |
| dc.identifier.doi.none.fl_str_mv |
10.25100/cm.v48i2.2774 |
| dc.identifier.eissn.none.fl_str_mv |
1657-9534 |
| identifier_str_mv |
1657-9534 10.25100/cm.v48i2.2774 |
| url |
http://hdl.handle.net/10495/19601 |
| dc.language.iso.spa.fl_str_mv |
eng spa |
| language |
eng spa |
| dc.relation.ispartofjournalabbrev.spa.fl_str_mv |
Colomb Med |
| dc.relation.citationendpage.spa.fl_str_mv |
81 |
| dc.relation.citationissue.spa.fl_str_mv |
2 |
| dc.relation.citationstartpage.spa.fl_str_mv |
70 |
| dc.relation.citationvolume.spa.fl_str_mv |
48 |
| dc.relation.ispartofjournal.spa.fl_str_mv |
Colombia Médica |
| dc.rights.uri.*.fl_str_mv |
http://creativecommons.org/licenses/by-nc-nd/2.5/co/ |
| dc.rights.uri.spa.fl_str_mv |
https://creativecommons.org/licenses/by-nc-nd/4.0/ |
| dc.rights.accessrights.spa.fl_str_mv |
info:eu-repo/semantics/openAccess |
| dc.rights.coar.spa.fl_str_mv |
http://purl.org/coar/access_right/c_abf2 |
| rights_invalid_str_mv |
http://creativecommons.org/licenses/by-nc-nd/2.5/co/ https://creativecommons.org/licenses/by-nc-nd/4.0/ http://purl.org/coar/access_right/c_abf2 |
| eu_rights_str_mv |
openAccess |
| dc.format.extent.spa.fl_str_mv |
12 |
| dc.format.mimetype.spa.fl_str_mv |
application/pdf |
| dc.publisher.spa.fl_str_mv |
Universidad del Valle, Facultad de Salud |
| dc.publisher.place.spa.fl_str_mv |
Cali, Colombia |
| institution |
Universidad de Antioquia |
| bitstream.url.fl_str_mv |
https://bibliotecadigital.udea.edu.co/bitstreams/ac1045c9-f5ff-4bc1-9436-adbcf0f2ac28/download https://bibliotecadigital.udea.edu.co/bitstreams/c34f0b27-3b81-4c56-ac77-15cea74d05e3/download https://bibliotecadigital.udea.edu.co/bitstreams/b8898aba-2477-44a6-8546-604e6b4be7eb/download https://bibliotecadigital.udea.edu.co/bitstreams/74240ef1-822b-4c67-a251-108a58919d47/download https://bibliotecadigital.udea.edu.co/bitstreams/cedd87e7-c83d-4ef9-9a9c-f8621f4b9540/download https://bibliotecadigital.udea.edu.co/bitstreams/1b60f3ac-bf1c-4fbe-b0cf-179b8d565b40/download https://bibliotecadigital.udea.edu.co/bitstreams/3b7626ec-fe72-432d-a864-57f2ed19f438/download https://bibliotecadigital.udea.edu.co/bitstreams/3c001233-fbaa-46cb-86a3-692d4fb549f4/download |
| bitstream.checksum.fl_str_mv |
b88b088d9957e670ce3b3fbe2eedbc13 8a4605be74aa9ea9d79846c1fba20a33 b7578d2c28c0b1a3dc41003a8c1a0d66 914b795742803f64784adc92f8a2bbb2 562add88c4e6b35540c742fe684eec6c 97319388bdee42532caee833b33becdc a24bf58fcb9d741d8988bdef48157e73 fb235dd032768d776d83912fa72fa35a |
| bitstream.checksumAlgorithm.fl_str_mv |
MD5 MD5 MD5 MD5 MD5 MD5 MD5 MD5 |
| repository.name.fl_str_mv |
Repositorio Institucional de la Universidad de Antioquia |
| repository.mail.fl_str_mv |
aplicacionbibliotecadigitalbiblioteca@udea.edu.co |
| _version_ |
1851052590326874112 |
| spelling |
Alzate Angel, Juan CarlosDuque Molina, Marcela MaríaGarcía García, Héctor IvánGrupo Académico de Epidemiología Clínica2021-05-14T15:44:18Z2021-05-14T15:44:18Z20171657-9534http://hdl.handle.net/10495/1960110.25100/cm.v48i2.27741657-9534ABSTRACT: Initial treatment of the HIV is based on the use of three drugs, two of which are nucleoside analog reverse-transcriptase inhibitors. There are three combinations of these drugs which have been approved by different guidelines, each with divergent results in terms of efficacy and safety. To compare the efficacy and safety of these three combinations. Systematic review and network meta-analysis of randomized clinical trials comparing fixed doses of Tenofovir Disoproxil Fumarate / Emtricitabine (TDF/FTC), Abacavir / Lamivudine (ABC/3TC) and Zidovudine / Lamivudine (ZDV/3TC). Seven clinical trials met the eligibility criteria. The results suggested higher efficacy with TDF/FTC vs. ABC/3TC at 96 weeks and vs. ZDV/3TC at 48 weeks. However, there is clinical and statistical heterogeneity. Subgroup analysis were performed by third drug and by level of viral load prior to treatment, and found no differences in virological control. Network meta-analysis could only be carried out with TDF/FTC vs. ZDV/3TC, and the proportion of patients with virological response, with no differences at 48 weeks nor at 96 weeks. Direct comparisons showed an increased risk of bone marrow suppression of ZDV/3TC vs. TDF/FTC and of ABC/3TC hypersensitivity reactions vs. ZDV/3TC. The results did not show differences in effectiveness among the interventions. However, due to the heterogeneity of the third drug and the follow-up time between the included studies, this result is not definitive. The results raise the need for further studies to help improve treatment recommendations in patients infected with HIV.RESUMEN: El tratamiento inicial de la infección por VIH se basa en el uso de tres medicamentos, dos de ellos inhibidores de transcriptasa reversa análogos de nucleósido. Existen tres combinaciones de estos medicamentos aprobadas por diferentes guías, con resultados divergentes en cuanto a eficacia y seguridad. Comparar la eficacia y seguridad de las 3 combinaciones. Revisión sistemática y metanálisis en red de ensayos clínicos con asignación aleatoria comparando dosis fijas de Tenofovir Disoproxil Fumarato/Emtricitabina (TDF/FTC), Abacavir/Lamivudina (ABC/3TC) y Zidovudina/Lamivudina (ZDV/3TC). Siete ensayos clínicos cumplieron los criterios de elegibilidad. Los resultados sugirieron mayor eficacia con TDF/FTC vs ABC/3TC a 96 semanas y vs. ZDV/3TC a 48 semanas. Sin embargo, existe heterogeneidad clínica y estadística. Se realizó análisis de subgrupos por tercer medicamento y por nivel de carga viral previa al tratamiento, sin encontrar diferencias en control virológico. Se pudo realizar metanálisis en red con TDF/FTC vs ZDV/3TC y proporción de pacientes con respuesta virológica, sin diferencias a las 48 semanas ni 96 semanas. Las comparaciones directas evidenciaron mayor riesgo de supresión de médula ósea de ZDV/3TC vs TDF/FTC y de reacciones de hipersensibilidad de ABC/3TC vs ZDV/3TC. Los resultados no demostraron diferencias en efectividad entre las intervenciones; sin embargo, debido a heterogeneidad en cuanto al tercer medicamento y el tiempo de seguimiento entre los estudios incluidos, dicho resultado no es definitivo. Los resultados plantean la necesidad de realizar nuevos estudios que ayuden a mejorar las recomendaciones de tratamiento en los pacientes infectados por el VIH.COL000712112application/pdfengspaUniversidad del Valle, Facultad de SaludCali, Colombiahttp://creativecommons.org/licenses/by-nc-nd/2.5/co/https://creativecommons.org/licenses/by-nc-nd/4.0/info:eu-repo/semantics/openAccesshttp://purl.org/coar/access_right/c_abf2Zidovudine/Lamivudine vs. Abacavir/Lamivudine vs. Tenofovir/Emtricitabine in fixed-dose combinations as initial treatment for HIV patients: a systematic review and network meta-analysisZidovudina/Lamivudina vs Abacavir/Lamivudina vs Tenofovir/Emtricitabina en combinaciones de dosis fija como tratamiento inicial en pacientes con VIH: revisión sistemática y metanálisis en redArtículo de revisiónhttp://purl.org/coar/resource_type/c_dcae04bchttp://purl.org/coar/resource_type/c_2df8fbb1https://purl.org/redcol/resource_type/ARTREVhttp://purl.org/coar/version/c_970fb48d4fbd8a85info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionVIHHIVEmtricitabinaEmtricitabineTenofovirZidovudinaZidovudineCombinación de MedicamentosDrug CombinationsRevisión SistemáticaSystematic ReviewColomb Med8127048Colombia MédicaPublicationCC-LICENSElicense_rdflicense_rdfapplication/rdf+xml; charset=utf-8823https://bibliotecadigital.udea.edu.co/bitstreams/ac1045c9-f5ff-4bc1-9436-adbcf0f2ac28/downloadb88b088d9957e670ce3b3fbe2eedbc13MD52falseAnonymousREADLICENSElicense.txtlicense.txttext/plain; charset=utf-81748https://bibliotecadigital.udea.edu.co/bitstreams/c34f0b27-3b81-4c56-ac77-15cea74d05e3/download8a4605be74aa9ea9d79846c1fba20a33MD53falseAnonymousREADORIGINALDuqueMarcela_2017_CombinationsInitialTreatmentForHIV.pdfDuqueMarcela_2017_CombinationsInitialTreatmentForHIV.pdfArtículo de revisión - Inglésapplication/pdf1418509https://bibliotecadigital.udea.edu.co/bitstreams/b8898aba-2477-44a6-8546-604e6b4be7eb/downloadb7578d2c28c0b1a3dc41003a8c1a0d66MD51trueAnonymousREADDuqueMarcela_2017_Zidovudina-Lamivudina-Abacavir.pdfDuqueMarcela_2017_Zidovudina-Lamivudina-Abacavir.pdfArtículo de revisión - Españolapplication/pdf1407249https://bibliotecadigital.udea.edu.co/bitstreams/74240ef1-822b-4c67-a251-108a58919d47/download914b795742803f64784adc92f8a2bbb2MD54falseAnonymousREADTEXTDuqueMarcela_2017_CombinationsInitialTreatmentForHIV.pdf.txtDuqueMarcela_2017_CombinationsInitialTreatmentForHIV.pdf.txtExtracted texttext/plain56337https://bibliotecadigital.udea.edu.co/bitstreams/cedd87e7-c83d-4ef9-9a9c-f8621f4b9540/download562add88c4e6b35540c742fe684eec6cMD55falseAnonymousREADDuqueMarcela_2017_Zidovudina-Lamivudina-Abacavir.pdf.txtDuqueMarcela_2017_Zidovudina-Lamivudina-Abacavir.pdf.txtExtracted texttext/plain59237https://bibliotecadigital.udea.edu.co/bitstreams/1b60f3ac-bf1c-4fbe-b0cf-179b8d565b40/download97319388bdee42532caee833b33becdcMD57falseAnonymousREADTHUMBNAILDuqueMarcela_2017_CombinationsInitialTreatmentForHIV.pdf.jpgDuqueMarcela_2017_CombinationsInitialTreatmentForHIV.pdf.jpgGenerated Thumbnailimage/jpeg15611https://bibliotecadigital.udea.edu.co/bitstreams/3b7626ec-fe72-432d-a864-57f2ed19f438/downloada24bf58fcb9d741d8988bdef48157e73MD56falseAnonymousREADDuqueMarcela_2017_Zidovudina-Lamivudina-Abacavir.pdf.jpgDuqueMarcela_2017_Zidovudina-Lamivudina-Abacavir.pdf.jpgGenerated Thumbnailimage/jpeg15503https://bibliotecadigital.udea.edu.co/bitstreams/3c001233-fbaa-46cb-86a3-692d4fb549f4/downloadfb235dd032768d776d83912fa72fa35aMD58falseAnonymousREAD10495/19601oai:bibliotecadigital.udea.edu.co:10495/196012025-03-27 00:44:03.12http://creativecommons.org/licenses/by-nc-nd/2.5/co/open.accesshttps://bibliotecadigital.udea.edu.coRepositorio Institucional de la Universidad de Antioquiaaplicacionbibliotecadigitalbiblioteca@udea.edu.coTk9URTogUExBQ0UgWU9VUiBPV04gTElDRU5TRSBIRVJFClRoaXMgc2FtcGxlIGxpY2Vuc2UgaXMgcHJvdmlkZWQgZm9yIGluZm9ybWF0aW9uYWwgcHVycG9zZXMgb25seS4KCk5PTi1FWENMVVNJVkUgRElTVFJJQlVUSU9OIExJQ0VOU0UKCkJ5IHNpZ25pbmcgYW5kIHN1Ym1pdHRpbmcgdGhpcyBsaWNlbnNlLCB5b3UgKHRoZSBhdXRob3Iocykgb3IgY29weXJpZ2h0Cm93bmVyKSBncmFudHMgdG8gRFNwYWNlIFVuaXZlcnNpdHkgKERTVSkgdGhlIG5vbi1leGNsdXNpdmUgcmlnaHQgdG8gcmVwcm9kdWNlLAp0cmFuc2xhdGUgKGFzIGRlZmluZWQgYmVsb3cpLCBhbmQvb3IgZGlzdHJpYnV0ZSB5b3VyIHN1Ym1pc3Npb24gKGluY2x1ZGluZwp0aGUgYWJzdHJhY3QpIHdvcmxkd2lkZSBpbiBwcmludCBhbmQgZWxlY3Ryb25pYyBmb3JtYXQgYW5kIGluIGFueSBtZWRpdW0sCmluY2x1ZGluZyBidXQgbm90IGxpbWl0ZWQgdG8gYXVkaW8gb3IgdmlkZW8uCgpZb3UgYWdyZWUgdGhhdCBEU1UgbWF5LCB3aXRob3V0IGNoYW5naW5nIHRoZSBjb250ZW50LCB0cmFuc2xhdGUgdGhlCnN1Ym1pc3Npb24gdG8gYW55IG1lZGl1bSBvciBmb3JtYXQgZm9yIHRoZSBwdXJwb3NlIG9mIHByZXNlcnZhdGlvbi4KCllvdSBhbHNvIGFncmVlIHRoYXQgRFNVIG1heSBrZWVwIG1vcmUgdGhhbiBvbmUgY29weSBvZiB0aGlzIHN1Ym1pc3Npb24gZm9yCnB1cnBvc2VzIG9mIHNlY3VyaXR5LCBiYWNrLXVwIGFuZCBwcmVzZXJ2YXRpb24uCgpZb3UgcmVwcmVzZW50IHRoYXQgdGhlIHN1Ym1pc3Npb24gaXMgeW91ciBvcmlnaW5hbCB3b3JrLCBhbmQgdGhhdCB5b3UgaGF2ZQp0aGUgcmlnaHQgdG8gZ3JhbnQgdGhlIHJpZ2h0cyBjb250YWluZWQgaW4gdGhpcyBsaWNlbnNlLiBZb3UgYWxzbyByZXByZXNlbnQKdGhhdCB5b3VyIHN1Ym1pc3Npb24gZG9lcyBub3QsIHRvIHRoZSBiZXN0IG9mIHlvdXIga25vd2xlZGdlLCBpbmZyaW5nZSB1cG9uCmFueW9uZSdzIGNvcHlyaWdodC4KCklmIHRoZSBzdWJtaXNzaW9uIGNvbnRhaW5zIG1hdGVyaWFsIGZvciB3aGljaCB5b3UgZG8gbm90IGhvbGQgY29weXJpZ2h0LAp5b3UgcmVwcmVzZW50IHRoYXQgeW91IGhhdmUgb2J0YWluZWQgdGhlIHVucmVzdHJpY3RlZCBwZXJtaXNzaW9uIG9mIHRoZQpjb3B5cmlnaHQgb3duZXIgdG8gZ3JhbnQgRFNVIHRoZSByaWdodHMgcmVxdWlyZWQgYnkgdGhpcyBsaWNlbnNlLCBhbmQgdGhhdApzdWNoIHRoaXJkLXBhcnR5IG93bmVkIG1hdGVyaWFsIGlzIGNsZWFybHkgaWRlbnRpZmllZCBhbmQgYWNrbm93bGVkZ2VkCndpdGhpbiB0aGUgdGV4dCBvciBjb250ZW50IG9mIHRoZSBzdWJtaXNzaW9uLgoKSUYgVEhFIFNVQk1JU1NJT04gSVMgQkFTRUQgVVBPTiBXT1JLIFRIQVQgSEFTIEJFRU4gU1BPTlNPUkVEIE9SIFNVUFBPUlRFRApCWSBBTiBBR0VOQ1kgT1IgT1JHQU5JWkFUSU9OIE9USEVSIFRIQU4gRFNVLCBZT1UgUkVQUkVTRU5UIFRIQVQgWU9VIEhBVkUKRlVMRklMTEVEIEFOWSBSSUdIVCBPRiBSRVZJRVcgT1IgT1RIRVIgT0JMSUdBVElPTlMgUkVRVUlSRUQgQlkgU1VDSApDT05UUkFDVCBPUiBBR1JFRU1FTlQuCgpEU1Ugd2lsbCBjbGVhcmx5IGlkZW50aWZ5IHlvdXIgbmFtZShzKSBhcyB0aGUgYXV0aG9yKHMpIG9yIG93bmVyKHMpIG9mIHRoZQpzdWJtaXNzaW9uLCBhbmQgd2lsbCBub3QgbWFrZSBhbnkgYWx0ZXJhdGlvbiwgb3RoZXIgdGhhbiBhcyBhbGxvd2VkIGJ5IHRoaXMKbGljZW5zZSwgdG8geW91ciBzdWJtaXNzaW9uLgo= |
